Follow-On And Wait: FDA Defers Action On Sandoz’s Human Growth Hormone
Executive Summary
Sandoz is presenting FDA's deferral of its decision on approval of the company's recombinant human growth hormone Omnitrope as essentially a tentative approval
You may also be interested in...
Omnitrope Lawsuit Could Further Delay FDA “Follow-On” Biologics Guidance
Sandoz' lawsuit against FDA over the human growth hormone product Omnitrope could further complicate the agency's efforts to define a potential approval route for "follow-on" biologics
Omnitrope Lawsuit Could Further Delay FDA “Follow-On” Biologics Guidance
Sandoz' lawsuit against FDA over the human growth hormone product Omnitrope could further complicate the agency's efforts to define a potential approval route for "follow-on" biologics
Generic Biologics Legislation Unlikely, But Issue Not Going Away
The push for legislation creating a follow-on biologics pathway is "cooling off," Senate Aging Committee majority counsel Steve Irizarry told the Stanford Washington Research Group conference in Washington, D.C. May 5